Elanco Animal Health Incorporated (BMV:ELAN)
Mexico · Delayed Price · Currency is MXN | Market Cap | 184.80B +98.5% |
| Revenue (ttm) | 88.21B +10.5% |
| Net Income | -4.36B |
| EPS | -8.80 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 19.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 533 |
| Average Volume | 539 |
| Open | 399.50 |
| Previous Close | 262.00 |
| Day's Range | 392.00 - 399.50 |
| 52-Week Range | 246.50 - 399.50 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | May 6, 2026 |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
News
Elanco Animal Health Transcript: AGM 2026
The meeting highlighted strong 2025 results, with growth in both pet and farm animal segments and innovation driving $1.2 billion in revenue. All board nominees and proposals were approved, and the company outlined plans for new blockbuster products and continued margin improvement.
Elanco launches Befrena for canine allergic itch
Elanco (ELAN) announced the phased launch of Befrena – tirnovetmab -, a new anti-IL-31 monoclonal antibody injection for treatment of canine allergic and atopic dermatitis. Befrena expands Elanco’s de...
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of...
Elanco price target lowered to $23 from $24 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $23 from $24 and keeps an Equal Weight rating on the shares.
Elanco to Participate in Upcoming Investor Conferences
INDIANAPOLIS, May 14, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, May 27, Jeff ...
Elanco Animal Health Q1 Earnings Call Highlights
Elanco Animal Health NYSE: ELAN raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based growth across pet health and farm animal businesses, accelerati...
Elanco price target raised to $30 from $28 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Elanco (ELAN) to $30 from $28 and keeps an Overweight rating on the shares.
Elanco price target raised to $31 from $30 at Citi
Citi raised the firm’s price target on Elanco (ELAN) to $31 from $30 and keeps a Buy rating on the shares. The firm says the company reported a “clean beat-and-raise”…
Elanco reports Q1 adjusted EPS 40c, consensus 34c
Reports Q1 revenue $1.37B, consensus $1.28B. “Elanco’s (ELAN) strong first quarter results demonstrate the significant momentum of our innovation-led strategy,” said Jeff Simmons, President and CEO of...
'WE WILL BE PREPARED': Inside efforts to stop screwworm outbreak
Elanco Animal Health CEO Jeff Simmons discusses response to screwworm outbreak concerns on 'The Claman Countdown.'
Elanco Animal Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 10% organic revenue growth, outpacing guidance, with strong performance across all segments and innovation products. Full-year guidance was raised for revenue, adjusted EBITDA, and EPS, while deleveraging continues and new retail and M&A initiatives expand reach.
Elanco Animal Health Earnings release: Q1 2026
Elanco Animal Health released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Elanco Animal Health Slides: Q1 2026
Elanco Animal Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Elanco Animal Health Quarterly report: Q1 2026
Elanco Animal Health has published its Q1 2026 quarterly earnings report on May 6, 2026.
Elanco Animal Health Reports First Quarter 2026 Results
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target First Quarter 2026 Financial Results: Revenue of $1,371 million, an increase of 15% year-over-year; 10% or...
Elanco Animal Health Slides: Investor presentation
Elanco Animal Health has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock
Action Prepares Veterinarians and Livestock Producers with Prevention and Treatment Options Prior to Fly Being Detected in the U.S. Federal agencies grant emergency authorizations for New World screww...
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a...
Elanco initiated with a Buy at Citi
Citi initiated coverage of Elanco (ELAN) with a Buy rating and $30 price target The firm launched the animal health and dental sectors with a “cautiously optimistic” view. Citi favors…
Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*
Breaks the flea lifecycle* with Pyriproxyfen, an insect growth regulator, preventing fleas from reinfesting the dog Adjustable collar fits comfortably and securely on a dog of any size Strengthens Ela...
Elanco Animal Health Proxy statement: Proxy filing
Elanco Animal Health filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Elanco Animal Health Proxy statement: Proxy filing
Elanco Animal Health filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Elanco Animal Health Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Innovation-driven growth exceeded expectations in 2025, with key products like Quattro and Zenrelia expanding market share and driving higher guidance for 2026. International expansion, robust R&D pipeline, and operational efficiencies—including AI adoption—support a positive multi-year outlook.
Elanco Animal Health Transcript: Leerink Global Healthcare Conference 2026
Strong Q4 results and raised 2026 innovation revenue targets reflect momentum across pet and farm segments. Operational efficiencies, robust product launches, and a disciplined capital strategy support margin expansion and future growth. Farm business and innovation pipeline are key drivers.
Elanco Animal Health Transcript: Barclays 28th Annual Global Healthcare Conference
Strong Q4 2025 results and robust innovation drove growth across all business segments, with key products like Quattro and Zenrelia expanding market share. 2026 guidance projects continued revenue, margin, and EPS growth, supported by operational efficiencies and a rich pipeline of future launches.